Scepter Holdings Inc decreased Valeant Pharmaceuticals Intl (VRX) stake by 16.67% reported in 2016Q4 SEC filing. Scepter Holdings Inc sold 100,000 shares as Valeant Pharmaceuticals Intl (VRX)’s stock rose 20.11%. The Scepter Holdings Inc holds 500,000 shares with $7.26M value, down from 600,000 last quarter. Valeant Pharmaceuticals Intl now has $3.35 billion valuation. The stock decreased 3.05% or $0.3 during the last trading session, reaching $9.55. About shares traded. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 67.59% since September 6, 2016 and is downtrending. It has underperformed by 75.25% the S&P500.
Analysts expect American Lorain Corporation (NYSEMKT:ALN) to report $0.00 EPS on April, 13. It closed at $0.56 lastly. It is down 9.68% since September 6, 2016 and is downtrending. It has underperformed by 17.33% the S&P500.
American Lorain Corporation is a food manufacturing company. The company has market cap of $21.43 million. The Firm develops, makes and sells a range of food products, including Chestnut products, Convenience foods and Frozen food products. It currently has negative earnings. The Firm operates through three divisions: Chestnut products, Convenience food products and Frozen food products.
Among 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 7 have Buy rating, 3 Sell and 13 Hold. Therefore 30% are positive. Valeant Pharmaceuticals Intl has $310 highest and $9 lowest target. $98’s average target is 926.18% above currents $9.55 stock price. Valeant Pharmaceuticals Intl had 86 analyst reports since July 21, 2015 according to SRatingsIntel. Guggenheim maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Friday, November 6 with “Buy” rating. The firm earned “Buy” rating on Tuesday, October 27 by Mizuho. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Equal-Weight” rating given on Monday, March 21 by Barclays Capital. The firm earned “Neutral” rating on Friday, October 9 by Mizuho. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Neutral” rating by Susquehanna on Wednesday, January 6. The firm has “Overweight” rating given on Wednesday, March 16 by JP Morgan. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Tuesday, October 27. RBC Capital Markets has “Outperform” rating and $231 target. The rating was maintained by RBC Capital Markets with “Sector Perform” on Wednesday, November 9. The firm earned “Buy” rating on Monday, April 11 by Rodman & Renshaw. The firm has “Overweight” rating given on Thursday, November 10 by Morgan Stanley.
Since December 12, 2016, it had 3 insider buys, and 2 insider sales for $218.09 million activity. 5,000 shares valued at $73,650 were bought by Ross Thomas W. Sr. on Wednesday, December 14. Pershing Square Capital Management – L.P. had sold 18.11 million shares worth $199.26M on Monday, March 13. On Tuesday, March 14 ValueAct Holdings – L.P. bought $32.47 million worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) or 3.00M shares. Shares for $257,280 were bought by Herendeen Paul.
Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on June, 6. They expect $0.99 EPS, down 22.05% or $0.28 from last year’s $1.27 per share. VRX’s profit will be $347.28 million for 2.41 P/E if the $0.99 EPS becomes a reality. After $1.26 actual EPS reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts -21.43% negative EPS growth.
Investors sentiment decreased to 0.78 in 2016 Q4. Its down 0.10, from 0.88 in 2016Q3. It fall, as 82 investors sold VRX shares while 87 reduced holdings. 49 funds opened positions while 82 raised stakes. 193.03 million shares or 13.22% less from 222.43 million shares in 2016Q3 were reported. Jones Collombin Inv Counsel reported 0.08% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Balyasny Asset Mngmt Llc holds 1.49M shares or 0.12% of its portfolio. Toronto Dominion Commercial Bank owns 7.55M shares for 0.32% of their portfolio. Franklin Street Nc holds 0.05% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 18,470 shares. Gargoyle Investment Advisor Limited Liability holds 0.07% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 13,161 shares. 32,624 are owned by Commonwealth Bancorporation Of Aus. Connor Clark And Lunn Investment Mgmt holds 0.03% or 332,426 shares in its portfolio. Raymond James & Associates reported 298,636 shares. Citadel Advsr Ltd Liability owns 1.77 million shares for 0.03% of their portfolio. Old Mutual Customised Solutions (Proprietary) Limited, South Africa-based fund reported 2,600 shares. Fil reported 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The California-based Aperio Lc has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Private Mgmt Gp Incorporated reported 0.56% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). 165,521 are owned by Oxford Asset Mngmt. Two Sigma Limited Liability Corp owns 104,840 shares.
